Elanco Animal Health Incorporated (NYSE:ELAN) CEO Acquires $1,301,000.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CEO Jeffrey N. Simmons bought 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Elanco Animal Health Trading Up 3.4 %

Shares of Elanco Animal Health stock opened at $14.56 on Friday. The company’s fifty day simple moving average is $14.68 and its 200-day simple moving average is $15.35. The stock has a market capitalization of $7.20 billion, a PE ratio of -5.49, a P/E/G ratio of 1.27 and a beta of 1.42. Elanco Animal Health Incorporated has a 1-year low of $8.52 and a 1-year high of $18.80. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the company earned $0.18 EPS. Elanco Animal Health’s revenue for the quarter was up 12.0% on a year-over-year basis. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Barclays cut their target price on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. Piper Sandler dropped their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $17.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ELAN. Norges Bank purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at $62,510,000. Canada Pension Plan Investment Board purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at $55,599,000. Dimensional Fund Advisors LP lifted its stake in shares of Elanco Animal Health by 33.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company’s stock valued at $224,920,000 after buying an additional 3,816,514 shares in the last quarter. Magnetar Financial LLC lifted its stake in shares of Elanco Animal Health by 61.2% during the 2nd quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock valued at $120,298,000 after buying an additional 3,164,350 shares in the last quarter. Finally, Primecap Management Co. CA increased its holdings in Elanco Animal Health by 2.9% in the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock valued at $753,945,000 after acquiring an additional 1,431,665 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.